Clinical Trial Update: Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a ruxolitinib-based graft-versus-host disease prophylaxis regimen before, during, and after hematopoietic cell transplantation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Aplastic Anemia | Phase 2 | Status: RECRUITING